A Phase 2 interventional study of Isatuximab SAR650984 and dexamethasone in T-cell Type Acute Leukemia-Precursor and T-lymphoblastic Lymphoma/Leukaemia, sponsored by Sanofi. Terminated at 17 sites in 7 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2022-03-21.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in France — 3 open to participants now, 5 under way, 1 of them phase 3. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · France.
Among the 23 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in France, this one is the 17th largest by enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2017, is one of 5 in phase 2, and was the 14th registered.
420 studies on the registry are indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; 75 are open to participants now.
Browse Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies →3 of the 23 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in France are open now. Recruiting first, the newest first:
Princess Maxima Center for Pediatric Oncology · Sites in France, Austria, Belgium and 11 more countries
Ages 1–21
Princess Maxima Center for Pediatric Oncology · Sites in France, Austria, Belgium and 11 more countries
Ages 1–21
Princess Maxima Center for Pediatric Oncology · Sites in France, Austria, Belgium and 12 more countries
Ages 1–21
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 59 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 24 (41%) set no upper age limit and 30 (51%) stop at 75 or younger; 35 take children under 18; 1 takes healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 3
First in 1994; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 30 across 322 interventional studies indexed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 43 across the 18 interventional studies, 62 across the 4 observational. Of the 15 that completed or were terminated, 5 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 23 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 1 study filed under Precursor T-Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 23 studies in Precursor T-Cell Lymphoblastic Leukemia-Lymphoma with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the efficacy of isatuximab.
Secondary Objectives:
The study duration per participant included a 3-week screening period, an approximately 1 year of treatment period or until disease progression or discontinuation for any other reason, and a follow-up period of at least 30 days after the last investigational medicinal product administration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received intravenous administration of isatuximab at a dose of 20 milligrams/kilogram (mg/kg) at Day 1, 8, 15 and 22 of each Cycle (up to 2 treatment cycles, each cycle 28 days).
Drug: Isatuximab SAR650984 · Drug: dexamethasone · Drug: acetaminophen · Drug: ranitidine · Drug: diphenhydramine
Pharmaceutical form:solution Route of administration: intravenous
Pharmaceutical form:pills Route of administration: oral
Pharmaceutical form:solution Route of administration: intravenous
Pharmaceutical form:pills Route of administration: oral
Pharmaceutical form:solution Route of administration: intravenous
Pharmaceutical form:solution Route of administration: intravenous
Percentage of Participants With Objective Response
Objective response was defined as percentage of participants with complete response (CR) or with complete response with incomplete peripheral recovery (CRi) as per National Comprehensive Cancer Network (NCCN) guidelines. CR was defined as no circulating blasts or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement, trilineage hematopoiesis and less than 5 percentage blasts, absolute neutrophil count (ANC) greater than 1000 per micro liter, platelets less than 100 000 per micro liter, no recurrence for 4 weeks. CRi meet all criteria for complete response except platelet count and/or ANC.
Time frame: Baseline until disease progression or death (maximum duration: 12.1 weeks)
Duration of Response (DOR)
DOR defined as time (in days) from date of first response until date of first documented progressive disease (PD) or death (from any cause), whichever came first. Progressive disease as per NCCN guidelines was defined as increase of at least 25 percentage (%) in the absolute number of circulating or bone marrow blasts or development of extramedullary disease.
Time frame: Baseline until disease progression or death (maximum duration: 12.1 weeks)
Progression Free Survival (PFS)
PFS was defined as the time interval (in days) from the date of first study drug administration to the date of first observation of PD or death due to any cause, whichever came first. PD as per NCCN guidelines was defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease.
Time frame: Baseline until disease progression or death (maximum duration: 12.1 weeks)
Overall Survival (OS)
Overall Survival was defined as the time interval from the date of first study drug administration to the date of death due to any cause.
Time frame: Baseline until death (maximum duration: 12.1 weeks)
Number of Participants With Minimal Residual Disease (MRD)
Presence of MRD was measured by sequencing and/or flow cytometry in participants achieving CR and CRi. CR was defined as no circulating blasts or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement, trilineage hematopoiesis and less than 5 percentage blasts, ANC greater than 1000 per micro liter, platelets less than 100 000 per micro liter, no recurrence for 4 weeks. Complete response with incomplete blood count recovery meet all criteria for complete response except platelet count and/or ANC.
Time frame: Baseline until death or study cut-off (maximum duration: 12.1 weeks)
The study was conducted in 6 countries. A total of 16 participants were screened of those 2 participants failed screening: 1 participant for evidence of ongoing infection and 1 participant for not meeting the criterion for relapsed or refractory T-acute lymphoblastic leukemia (ALL)/T-lymphoblastic lymphoma (LBL).
| Milestone | Isatuximab |
|---|---|
| Started | 14 |
| Completed | 0 |
| Not completed | 14 |
| Withdrew: Adverse event | 2 |
| Withdrew: Progressive disease | 12 |
Objective response was defined as percentage of participants with complete response (CR) or with complete response with incomplete peripheral recovery (CRi) as per National Comprehensive Cancer Network (NCCN) guidelines. CR was defined as no circulating blasts or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement, trilineage hematopoiesis and less than 5 percentage blasts, absolute neutrophil count (ANC) greater than 1000 per micro liter, platelets less than 100 000 per micro liter, no recurrence for 4 weeks. CRi meet all criteria for complete response except platelet count and/or ANC.
| percentage of participants | Isatuximab |
|---|---|
| Percentage of Participants With Objective Response | 0 (0 to 23.2) |
DOR defined as time (in days) from date of first response until date of first documented progressive disease (PD) or death (from any cause), whichever came first. Progressive disease as per NCCN guidelines was defined as increase of at least 25 percentage (%) in the absolute number of circulating or bone marrow blasts or development of extramedullary disease.
No measurements were reported for this outcome.
PFS was defined as the time interval (in days) from the date of first study drug administration to the date of first observation of PD or death due to any cause, whichever came first. PD as per NCCN guidelines was defined as increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease.
No measurements were reported for this outcome.
Overall Survival was defined as the time interval from the date of first study drug administration to the date of death due to any cause.
No measurements were reported for this outcome.
Presence of MRD was measured by sequencing and/or flow cytometry in participants achieving CR and CRi. CR was defined as no circulating blasts or extramedullary disease, no lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/central nervous system involvement, trilineage hematopoiesis and less than 5 percentage blasts, ANC greater than 1000 per micro liter, platelets less than 100 000 per micro liter, no recurrence for 4 weeks. Complete response with incomplete blood count recovery meet all criteria for complete response except platelet count and/or ANC.
No measurements were reported for this outcome.
Collected over Baseline up to 30 days after last dose of study drug administration (up to maximum of 12.1 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Isatuximab | 6/14 (42.9%) | 10/14 (71.4%) | 12/14 (85.7%) |
| Event | Isatuximab |
|---|---|
| Disease ProgressionGeneral disorders | 4/14 |
| Acute Myocardial InfarctionCardiac disorders | 1/14 |
| Pericarditis ConstrictiveCardiac disorders | 1/14 |
| PancreatitisGastrointestinal disorders | 1/14 |
| Device Related InfectionInfections and infestations | 1/14 |
| Fungal InfectionInfections and infestations | 1/14 |
| Periorbital CellulitisInfections and infestations | 1/14 |
| PneumoniaInfections and infestations | 1/14 |
| SepsisInfections and infestations | 1/14 |
| Acute Respiratory FailureRespiratory, thoracic and mediastinal disorders | 1/14 |
| Event | Isatuximab |
|---|---|
| Infusion Related ReactionInjury, poisoning and procedural complications | 8/14 |
| PyrexiaGeneral disorders | 5/14 |
| TachycardiaCardiac disorders | 2/14 |
| ConstipationGastrointestinal disorders | 2/14 |
| DiarrhoeaGastrointestinal disorders | 2/14 |
| Back PainMusculoskeletal and connective tissue disorders | 2/14 |
| Bone PainMusculoskeletal and connective tissue disorders | 2/14 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/14 |
| AnaemiaBlood and lymphatic system disorders | 1/14 |
| NeutropeniaBlood and lymphatic system disorders | 1/14 |
Safety analysis set included all participants who received at least 1 dose of isatuximab.
| Age, Continuous(years) | Isatuximab |
|---|---|
| Mean | 41.36 ± 19.30 |
| Sex: Female, Male(Participants) | Isatuximab |
|---|---|
| Female | 2 |
| Male | 12 |
| Race (NIH/OMB)(Participants) | Isatuximab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 6 |
| More than one race | 0 |
| Unknown or Not Reported | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Mar 2017 to primary completion in Nov 2017, 8 months.
Results were first posted in Jan 2020, 2 years 2 months after primary completion. A results delay was requested in Nov 2018.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Isatuximab
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma →